Autolus Therapeutics Plc (AUTL)
1.55
-0.02
(-1.27%)
USD |
NASDAQ |
Dec 05, 16:00
1.545
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value: 368.79M for Dec. 5, 2025
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Adaptimmune Therapeutics Plc | 35.67M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -16.45M |
| Mereo BioPharma Group Plc | 279.24M |
| Bicycle Therapeutics Plc | -151.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.64M |
| Revenue (Quarterly) | 21.07M |
| Total Expenses (Quarterly) | 99.71M |
| EPS Diluted (Quarterly) | -0.2955 |
| Gross Profit Margin (Quarterly) | -51.21% |
| Profit Margin (Quarterly) | -373.3% |
| Earnings Yield | -54.46% |
| Normalized Earnings Yield | -54.46 |